Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 1-Year High – What’s Next?

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $59.71 and last traded at $59.43, with a volume of 15673 shares. The stock had previously closed at $58.60.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KNSA shares. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Canaccord Genuity Group boosted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Finally, Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.86.

Kiniksa Pharmaceuticals International Trading Up 1.9%

The stock has a 50-day simple moving average of $47.97 and a 200-day simple moving average of $44.01. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 66.09 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the previous year, the firm posted $0.11 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the sale, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the sale, the chief accounting officer owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This trade represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 655,991 shares of company stock valued at $34,167,123. 53.48% of the stock is currently owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently modified their holdings of KNSA. Amundi acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares during the period. Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at $358,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at $43,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.